Literature DB >> 15048126

SREBPs suppress IRS-2-mediated insulin signalling in the liver.

Tomohiro Ide1, Hitoshi Shimano, Naoya Yahagi, Takashi Matsuzaka, Masanori Nakakuki, Takashi Yamamoto, Yoshimi Nakagawa, Akimitsu Takahashi, Hiroaki Suzuki, Hirohito Sone, Hideo Toyoshima, Akiyoshi Fukamizu, Nobuhiro Yamada.   

Abstract

Insulin receptor substrate 2 (IRS-2) is the main mediator of insulin signalling in the liver, controlling insulin sensitivity. Sterol regulatory element binding proteins (SREBPs) have been established as transcriptional regulators of lipid synthesis. Here, we show that SREBPs directly repress transcription of IRS-2 and inhibit hepatic insulin signalling. The IRS-2 promoter is activated by forkhead proteins through an insulin response element (IRE). Nuclear SREBPs effectively replace and interfere in the binding of these transactivators, resulting in inhibition of the downstream PI(3)K/Akt pathway, followed by decreased glycogen synthesis. These data suggest a molecular mechanism for the physiological switching from glycogen synthesis to lipogenesis and hepatic insulin resistance that is associated with hepatosteatosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048126     DOI: 10.1038/ncb1111

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  115 in total

1.  FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis.

Authors:  Kyoichiro Tsuchiya; Jun Tanaka; Yu Shuiqing; Carrie L Welch; Ronald A DePinho; Ira Tabas; Alan R Tall; Ira J Goldberg; Domenico Accili
Journal:  Cell Metab       Date:  2012-03-07       Impact factor: 27.287

2.  Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism.

Authors:  Cullen M Taniguchi; Kohjiro Ueki; Ronald Kahn
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 3.  Signalling mechanisms linking hepatic glucose and lipid metabolism.

Authors:  M O Weickert; A F H Pfeiffer
Journal:  Diabetologia       Date:  2006-05-23       Impact factor: 10.122

4.  Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth.

Authors:  Xiaocheng Dong; Sunmin Park; Xueying Lin; Kyle Copps; Xianjin Yi; Morris F White
Journal:  J Clin Invest       Date:  2005-12-22       Impact factor: 14.808

5.  Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance.

Authors:  Yasuo Terauchi; Iseki Takamoto; Naoto Kubota; Junji Matsui; Ryo Suzuki; Kajuro Komeda; Akemi Hara; Yukiyasu Toyoda; Ichitomo Miwa; Shinichi Aizawa; Shuichi Tsutsumi; Yoshiharu Tsubamoto; Shinji Hashimoto; Kazuhiro Eto; Akinobu Nakamura; Mitsuhiko Noda; Kazuyuki Tobe; Hiroyuki Aburatani; Ryozo Nagai; Takashi Kadowaki
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

6.  Nutrigenomics, beta-cell function and type 2 diabetes.

Authors:  R Nino-Fong; Tm Collins; Cb Chan
Journal:  Curr Genomics       Date:  2007-03       Impact factor: 2.236

7.  Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs.

Authors:  Xuefen Xie; Hailing Liao; Huaixin Dang; Wei Pang; Youfei Guan; Xian Wang; John Y-J Shyy; Yi Zhu; Frances M Sladek
Journal:  Mol Endocrinol       Date:  2009-01-29

Review 8.  Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.

Authors:  Shaodong Guo
Journal:  J Endocrinol       Date:  2014-01-08       Impact factor: 4.286

9.  Chromatin remodeling complex interacts with ADD1/SREBP1c to mediate insulin-dependent regulation of gene expression.

Authors:  Yun Sok Lee; Dong Hyun Sohn; Daehee Han; Han-Woong Lee; Rho Hyun Seong; Jae Bum Kim
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

10.  PERK-dependent regulation of lipogenesis during mouse mammary gland development and adipocyte differentiation.

Authors:  Ekaterina Bobrovnikova-Marjon; Georgia Hatzivassiliou; Christina Grigoriadou; Margarita Romero; Douglas R Cavener; Craig B Thompson; J Alan Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.